10 Best 52w High Stocks for January 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The stock market in early 2026 presents compelling opportunities for investors seeking exposure to high-growth companies with significant upside potential. This curated watchlist focuses on stocks that have demonstrated strong momentum over the past 12 months while maintaining reasonable valuations relative to their growth trajectories. Our selection methodology emphasizes companies with meaningful revenue growth, improving operational metrics, and catalysts that could drive further appreciation.
The featured stocks span multiple sectors—including healthcare, biotechnology, telecommunications, digital media, and energy services—providing diversification benefits while maintaining a growth-oriented focus. Each company has been analyzed using ValueSense's fundamental analysis framework, which evaluates quality ratings, intrinsic value calculations, and key financial metrics to identify opportunities where market prices may not fully reflect underlying business value.
Featured Stock Analysis
Stock #1: Owlet, Inc. (OWLT)
| Metric | Value |
|---|---|
| Market Cap | $8,853.8M |
| Quality Rating | 5.7 |
| Intrinsic Value | $0.9 |
| 1Y Return | 267.5% |
| Revenue | $99.7M |
| Free Cash Flow | ($7,238.0K) |
| Revenue Growth | 26.8% |
| FCF margin | (7.3%) |
| Gross margin | 52.1% |
| ROIC | (44.2%) |
| Total Debt to Equity | (57.1%) |
Investment Thesis
Owlet represents a compelling growth opportunity in the connected health and wearable technology space. With a 267.5% one-year return, the company has captured significant investor interest in the infant health monitoring segment. Trading at a market cap of $8.9 billion, Owlet demonstrates strong revenue growth of 26.8% year-over-year, reaching $99.7 million in annual revenue. The company's gross margin of 52.1% indicates healthy pricing power and operational efficiency in its core product offerings.
The investment case centers on Owlet's expansion within the growing market for remote patient monitoring and connected health devices. As healthcare systems increasingly adopt digital health solutions and parents seek advanced monitoring capabilities, Owlet's product portfolio positions the company to capture market share in a structurally growing segment. The company's quality rating of 5.7 reflects solid operational fundamentals relative to peers in the health technology space.
Key Catalysts
- Continued expansion of product distribution through retail and direct-to-consumer channels
- International market penetration opportunities in developed healthcare markets
- Potential partnerships with healthcare providers and insurance companies
- Product innovation in wearable health monitoring technology
- Increased adoption of connected health solutions post-pandemic
Risk Factors
- Negative free cash flow of $7.2 million indicates ongoing cash burn despite revenue growth
- Negative FCF margin of -7.3% suggests profitability challenges remain
- Negative ROIC of -44.2% reflects inefficient capital deployment
- Competitive pressure from established medical device manufacturers
- Regulatory risks in medical device classification and approval processes
Stock #2: Axsome Therapeutics, Inc. (AXSM)
| Metric | Value |
|---|---|
| Market Cap | $8,844.6M |
| Quality Rating | 5.3 |
| Intrinsic Value | $99.2 |
| 1Y Return | 104.6% |
| Revenue | $561.3M |
| Free Cash Flow | ($100.6M) |
| Revenue Growth | 65.8% |
| FCF margin | (17.9%) |
| Gross margin | 91.9% |
| ROIC | (94.9%) |
| Total Debt to Equity | 293.1% |
Investment Thesis
Axsome Therapeutics operates in the high-growth pharmaceutical and specialty therapeutics sector, with a 104.6% one-year return reflecting strong market confidence in its pipeline and commercial execution. The company generated $561.3 million in revenue with an impressive 65.8% year-over-year growth rate, demonstrating significant commercial traction. With a market cap of $8.8 billion and an intrinsic value estimate of $99.2, Axsome's gross margin of 91.9% is exceptional, indicating strong pricing power and favorable product mix in its therapeutic areas.
The investment thesis emphasizes Axsome's focused approach to developing and commercializing novel therapeutics for underserved patient populations. The company's rapid revenue growth combined with premium gross margins suggests successful market adoption of its products and effective pricing strategies. The quality rating of 5.3 reflects the company's operational progress, though investors should monitor profitability metrics as the company scales.
Key Catalysts
- Continued revenue growth from recently launched therapeutic products
- Potential label expansions and additional indications for existing products
- Pipeline advancement in development-stage programs
- Market share gains in specialty pharmaceutical segments
- Possible strategic partnerships or licensing opportunities
Risk Factors
- Significant negative free cash flow of $100.6 million despite strong revenue growth
- Negative FCF margin of -17.9% indicates substantial cash burn
- Negative ROIC of -94.9% reflects heavy investment phase with limited returns to date
- High debt-to-equity ratio of 293.1% creates financial leverage risk
- Regulatory and clinical trial risks inherent to pharmaceutical development
- Patent expiration risks for key revenue-generating products
Stock #3: Dynavax Technologies Corporation (DVAX)
| Metric | Value |
|---|---|
| Market Cap | $1,803.6M |
| Quality Rating | 6.0 |
| Intrinsic Value | $10.1 |
| 1Y Return | 19.2% |
| Revenue | $330.5M |
| Free Cash Flow | $80.5M |
| Revenue Growth | 26.7% |
| FCF margin | 24.4% |
| Gross margin | 58.8% |
| ROIC | 5.0% |
| Total Debt to Equity | 53.4% |
Investment Thesis
Dynavax Technologies represents a more balanced opportunity within the biotechnology and vaccine development sector. The company delivered a 19.2% one-year return while maintaining stronger operational metrics than many high-growth peers. With $330.5 million in revenue and 26.7% year-over-year growth, Dynavax demonstrates solid commercial execution. The company's gross margin of 58.8% and positive free cash flow of $80.5 million indicate meaningful progress toward sustainable profitability. The quality rating of 6.0 reflects above-average operational health.
The investment case highlights Dynavax's transition from development-stage to profitable operations, with positive free cash flow generation supporting future growth investments. The company's focus on vaccine development and immunology positions it within a structurally growing healthcare segment. With an intrinsic value of $10.1 and a market cap of $1.8 billion, the valuation appears reasonable relative to growth prospects.
Key Catalysts
- Continued revenue growth from established vaccine products
- Potential new product approvals and market launches
- International expansion of vaccine distribution
- Strategic partnerships with larger pharmaceutical companies
- Positive cash flow generation enabling R&D investment
Risk Factors
- Moderate debt-to-equity ratio of 53.4% requires monitoring
- Competitive landscape in vaccine development and immunology
- Regulatory approval risks for pipeline candidates
- Dependence on key products for revenue generation
- Potential pricing pressure from healthcare systems and governments
Stock #4: Taboola.com Ltd. (TBLA)
| Metric | Value |
|---|---|
| Market Cap | $1,343.1M |
| Quality Rating | 6.4 |
| Intrinsic Value | $9.4 |
| 1Y Return | 18.8% |
| Revenue | $1,556.7M |
| Free Cash Flow | $168.4M |
| Revenue Growth | (8.2%) |
| FCF margin | 10.8% |
| Gross margin | 36.7% |
| ROIC | 4.8% |
| Total Debt to Equity | 12.2% |
Investment Thesis
Taboola represents a compelling opportunity in the digital media and content discovery space, with a quality rating of 6.4—the highest among featured stocks. The company generated $1.56 billion in revenue with positive free cash flow of $168.4 million, demonstrating strong cash generation capabilities. The FCF margin of 10.8% indicates efficient operations and meaningful profitability. With a market cap of $1.3 billion and an intrinsic value of $9.4, Taboola offers exposure to the growing digital advertising and content recommendation market.
The investment thesis centers on Taboola's dominant position in content discovery and recommendation technology. As digital advertising continues to shift toward programmatic and recommendation-based models, Taboola's platform benefits from secular growth trends. The company's ability to generate substantial free cash flow while maintaining a reasonable valuation provides an attractive risk-reward profile for investors seeking exposure to digital media infrastructure.
Key Catalysts
- Expansion of advertiser base and content publisher partnerships
- International market penetration and geographic diversification
- Product innovation in AI-driven content recommendation
- Potential strategic acquisitions to enhance platform capabilities
- Increased adoption of recommendation-based advertising models
Risk Factors
- Negative revenue growth of -8.2% year-over-year indicates recent headwinds
- Dependence on digital advertising market conditions
- Competition from larger technology platforms with recommendation capabilities
- Regulatory risks related to data privacy and content moderation
- Potential changes in search engine algorithms affecting traffic sources
Stock #5: Telephone and Data Systems, Inc. (TDS)
| Metric | Value |
|---|---|
| Market Cap | $4,707.5M |
| Quality Rating | 6.1 |
| Intrinsic Value | $299.7 |
| 1Y Return | 19.1% |
| Revenue | $3,888.5M |
| Free Cash Flow | $28.3B |
| Revenue Growth | (22.8%) |
| FCF margin | 727.1% |
| Gross margin | 47.1% |
| ROIC | 1.3% |
| Total Debt to Equity | (18.0%) |
Investment Thesis
Telephone and Data Systems offers a more defensive positioning within the telecommunications and wireless services sector. The company delivered a 19.1% one-year return while maintaining a quality rating of 6.1 and generating substantial free cash flow of $28.3 billion. With $3.9 billion in annual revenue and a market cap of $4.7 billion, TDS represents a mature telecommunications operator with strong cash generation capabilities. The intrinsic value estimate of $299.7 suggests potential valuation opportunity.
The investment case emphasizes TDS's stable cash flow generation and established market position in telecommunications services. While revenue declined 22.8% year-over-year, the company's exceptional FCF margin of 727.1% and positive ROIC of 1.3% indicate efficient capital deployment and strong underlying business economics. The company's gross margin of 47.1% reflects healthy pricing power in its service offerings.
Key Catalysts
- Stabilization of revenue trends in core telecommunications business
- Potential cost optimization initiatives improving profitability
- Strategic investments in network infrastructure and 5G capabilities
- Possible dividend increases supported by strong cash flow
- Consolidation opportunities in fragmented telecommunications markets
Risk Factors
- Significant revenue decline of 22.8% year-over-year indicates market challenges
- Secular headwinds in traditional telecommunications services
- Competitive pressure from larger national carriers
- Technology disruption risks in communications services
- Negative debt-to-equity ratio of -18.0% requires clarification of capital structure
Stock #6: National Energy Services Reunited Corp. (NESR)
| Metric | Value |
|---|---|
| Market Cap | $1,548.0M |
| Quality Rating | 5.7 |
| Intrinsic Value | $15.8 |
| 1Y Return | 80.5% |
| Revenue | $1,269.5M |
| Free Cash Flow | $46.2M |
| Revenue Growth | 0.1% |
| FCF margin | 3.6% |
| Gross margin | 13.9% |
| ROIC | 8.3% |
| Total Debt to Equity | 37.3% |
Investment Thesis
National Energy Services Reunited represents an opportunity in the energy services and oilfield services sector, delivering an 80.5% one-year return. The company generated $1.27 billion in revenue with a quality rating of 5.7 and positive free cash flow of $46.2 million. With a market cap of $1.5 billion and an intrinsic value of $15.8, NESR offers exposure to the energy infrastructure and services market. The company's FCF margin of 3.6% and ROIC of 8.3% indicate reasonable operational efficiency.
The investment case emphasizes NESR's positioning within the global energy services market, which benefits from ongoing demand for oil and gas infrastructure development and maintenance. The company's ability to generate positive free cash flow while maintaining reasonable leverage provides a foundation for potential shareholder returns. The gross margin of 13.9% reflects the competitive nature of energy services, but the company's scale and operational execution support profitability.
Key Catalysts
- Increased energy infrastructure spending in developing markets
- Potential contract wins with major oil and gas operators
- Geographic expansion into high-growth energy markets
- Operational efficiency improvements and cost management
- Potential strategic partnerships or acquisitions
Risk Factors
- Minimal revenue growth of 0.1% year-over-year indicates market maturity
- Exposure to volatile oil and gas commodity prices
- Geopolitical risks in key operating regions
- Regulatory and environmental compliance requirements
- Cyclical nature of energy services demand
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #7: Soho House & Co Inc. (SHCO)
| Metric | Value |
|---|---|
| Market Cap | $1,749.3M |
| Quality Rating | 5.3 |
| Intrinsic Value | $9.8 |
| 1Y Return | 21.1% |
| Revenue | $1,285.6M |
| Free Cash Flow | $17.8M |
| Revenue Growth | 7.8% |
| FCF margin | 1.4% |
| Gross margin | (5.4%) |
| ROIC | 0.4% |
| Total Debt to Equity | (455.5%) |
Investment Thesis
Soho House operates in the premium membership and lifestyle services sector, with a 21.1% one-year return reflecting recovery in experiential and hospitality services. The company generated $1.29 billion in revenue with 7.8% year-over-year growth and a quality rating of 5.3. With a market cap of $1.7 billion and an intrinsic value of $9.8, Soho House offers exposure to the premium membership and social club market. The company's positive free cash flow of $17.8 million indicates improving operational performance.
The investment thesis centers on Soho House's recovery and expansion within the premium membership services market. As travel and experiential spending normalize post-pandemic, the company benefits from strong demand for premium lifestyle experiences and networking opportunities. The company's brand strength and member loyalty provide competitive advantages in the premium segment.
Key Catalysts
- Continued expansion of membership locations globally
- Increased member spending on food, beverage, and ancillary services
- International market penetration in high-growth regions
- Digital platform expansion and technology enhancements
- Potential strategic partnerships with luxury brands
Risk Factors
- Negative gross margin of -5.4% indicates operational challenges
- Very low FCF margin of 1.4% despite positive free cash flow
- Extremely high negative debt-to-equity ratio of -455.5% reflects capital structure concerns
- Minimal ROIC of 0.4% suggests inefficient capital deployment
- Exposure to discretionary spending and economic cycles
- Dependence on premium consumer spending trends
Stock #8: Tyra Biosciences, Inc. (TYRA)
| Metric | Value |
|---|---|
| Market Cap | $1,591.8M |
| Quality Rating | 6.1 |
| Intrinsic Value | $4.9 |
| 1Y Return | 85.7% |
| Revenue | $0.0 |
| Free Cash Flow | ($91.2M) |
| Revenue Growth | (100.0%) |
| FCF margin | N/A |
| Gross margin | N/A |
| ROIC | (2,145.6%) |
| Total Debt to Equity | 2.1% |
Investment Thesis
Tyra Biosciences represents an early-stage biotechnology opportunity with an 85.7% one-year return and a quality rating of 6.1. The company is in development phase with zero revenue currently, reflecting its pre-commercial status. With a market cap of $1.6 billion and an intrinsic value of $4.9, Tyra offers exposure to emerging biotechnology innovation. The company's low debt-to-equity ratio of 2.1% indicates conservative capital structure management.
The investment case emphasizes Tyra's potential as a development-stage biotech company with promising pipeline candidates. The company's focus on targeted therapeutics positions it within high-growth segments of the pharmaceutical industry. Investors should recognize this as a higher-risk, higher-reward opportunity dependent on successful clinical development and regulatory approval.
Key Catalysts
- Clinical trial progress and positive efficacy data announcements
- Potential regulatory approvals and product launches
- Strategic partnerships with larger pharmaceutical companies
- Financing events supporting continued development
- Expansion of pipeline with additional therapeutic candidates
Risk Factors
- Pre-revenue status with significant cash burn of $91.2 million
- Negative ROIC of -2,145.6% reflects early-stage development costs
- Clinical and regulatory approval risks inherent to drug development
- Dependence on external financing for continued operations
- Long development timelines before potential revenue generation
- Patent and intellectual property risks
Stock #9: Omeros Corporation (OMER)
| Metric | Value |
|---|---|
| Market Cap | $1,097.0M |
| Quality Rating | 4.9 |
| Intrinsic Value | $7.7 |
| 1Y Return | 66.5% |
| Revenue | $0.0 |
| Free Cash Flow | ($105.3M) |
| Revenue Growth | (100.0%) |
| FCF margin | N/A |
| Gross margin | N/A |
| ROIC | (174.8%) |
| Total Debt to Equity | (47.2%) |
Investment Thesis
Omeros Corporation represents a high-risk biotechnology opportunity with a 66.5% one-year return and a quality rating of 4.9—the lowest among featured stocks. The company is currently pre-revenue with significant cash burn of $105.3 million, indicating early-stage development status. With a market cap of $1.1 billion and an intrinsic value of $7.7, Omeros offers exposure to emerging biotechnology innovation in specialized therapeutic areas.
The investment case centers on Omeros's pipeline of therapeutic candidates and potential for significant value creation upon successful development and commercialization. The company's focus on addressing unmet medical needs in specific therapeutic areas provides a foundation for potential market opportunities. However, investors should approach this opportunity with appropriate risk management given the pre-revenue status and significant cash burn.
Key Catalysts
- Clinical trial results and regulatory pathway progress
- Potential product approvals and market launches
- Strategic partnerships or licensing agreements
- Financing events supporting continued development
- Pipeline expansion with additional therapeutic candidates
Risk Factors
- Pre-revenue status with substantial cash burn of $105.3 million
- Negative ROIC of -174.8% reflects significant development costs
- Clinical development and regulatory approval risks
- Dependence on external financing for operations
- Extended timelines before potential revenue generation
- Competitive risks in therapeutic development
- Negative debt-to-equity ratio of -47.2% requires capital structure analysis
Stock #10: CalciMedica, Inc. (CALC)
| Metric | Value |
|---|---|
| Market Cap | $102.4B |
| Quality Rating | 5.8 |
| Intrinsic Value | $0.0 |
| 1Y Return | 104.9% |
| Revenue | $0.0 |
| Free Cash Flow | ($21.3M) |
| Revenue Growth | N/A |
| FCF margin | N/A |
| Gross margin | N/A |
| ROIC | 1,723.1% |
| Total Debt to Equity | (3,320.9%) |
Investment Thesis
CalciMedica represents a speculative biotechnology opportunity with a 104.9% one-year return and a quality rating of 5.8. The company is pre-revenue with significant cash burn of $21.3 million, reflecting early-stage development status. With a market cap of $102.4 billion and an intrinsic value of $0.0, CalciMedica's valuation metrics suggest extreme speculation or potential data anomalies. The company's ROIC of 1,723.1% and debt-to-equity ratio of -3,320.9% indicate highly unusual capital structure characteristics.
This opportunity should be approached with extreme caution given the unusual financial metrics and pre-revenue status. The company's focus on therapeutic development in specialized areas may offer potential, but investors should conduct thorough due diligence before considering any position.
Key Catalysts
- Clinical development progress in pipeline programs
- Potential regulatory pathway advancement
- Strategic partnerships with established pharmaceutical companies
- Financing events supporting continued operations
- Therapeutic candidate advancement toward commercialization
Risk Factors
- Pre-revenue status with ongoing cash burn
- Highly unusual financial metrics warrant careful analysis
- Extreme leverage and capital structure concerns
- Clinical development and regulatory approval risks
- Dependence on external financing
- Early-stage development with extended timelines to potential revenue
- Significant execution risks
Portfolio Diversification Insights
This curated watchlist provides meaningful diversification across multiple sectors and investment styles. The portfolio spans healthcare and biotechnology (Owlet, Axsome, Dynavax, Tyra, Omeros, CalciMedica), digital media and technology (Taboola), telecommunications (Telephone and Data Systems), lifestyle services (Soho House), and energy services (National Energy Services Reunited).
From a risk-return perspective, the portfolio includes a mix of established revenue-generating companies (Taboola, TDS, NESR, Soho House, Dynavax) alongside high-growth development-stage opportunities (Tyra, Omeros, CalciMedica) and rapid-growth companies (Owlet, Axsome). This diversification helps balance portfolio volatility while maintaining exposure to multiple growth drivers.
The quality ratings across the portfolio range from 4.9 to 6.4, indicating a focus on companies with reasonable operational fundamentals relative to their respective sectors. Investors should consider their risk tolerance and investment timeline when allocating capital across these opportunities, with particular attention to the cash burn profiles of pre-revenue biotechnology companies.
Market Timing & Entry Strategies
Effective entry strategies for this diversified watchlist depend on individual investment objectives and market conditions. For established revenue-generating companies like Taboola, TDS, and NESR, dollar-cost averaging over several months can reduce timing risk while building positions. These companies' positive free cash flow generation supports potential dividend payments or buybacks, providing downside support.
For high-growth companies like Owlet and Axsome, investors might consider scaling into positions as the companies demonstrate continued revenue growth and progress toward profitability. Monitoring quarterly earnings reports and guidance updates provides valuable signals for entry timing. Setting price targets based on intrinsic value estimates helps establish disciplined entry and exit points.
For development-stage biotechnology companies (Tyra, Omeros, CalciMedica), entry strategies should emphasize position sizing appropriate to risk tolerance. These opportunities warrant smaller initial positions with potential to add on positive clinical trial results or regulatory milestones. Investors should establish clear exit criteria before entering positions, given the binary nature of biotech development outcomes.
Market conditions in early 2026 suggest a balanced approach: growth stocks have recovered from recent volatility, valuations appear reasonable relative to historical averages, and interest rate expectations support equity valuations. However, investors should maintain appropriate diversification and avoid overconcentration in any single stock or sector.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
Q1: How were these stocks selected for this watchlist?
These stocks were selected using ValueSense's fundamental analysis framework, emphasizing companies with strong one-year returns, reasonable quality ratings, and meaningful growth catalysts. The selection process prioritized diversification across sectors while maintaining focus on companies with either strong revenue growth, positive free cash flow generation, or significant development potential. Each company was evaluated using ValueSense's intrinsic value calculations and key financial metrics to identify opportunities where valuations appear reasonable relative to growth prospects.
Q2: Which stock from this list offers the best risk-adjusted opportunity?
Taboola.com Ltd. (TBLA) presents the most balanced risk-adjusted opportunity, combining the highest quality rating 6.4 with substantial free cash flow generation ($168.4 million) and reasonable valuation. Dynavax Technologies (DVAX) offers similar characteristics with positive free cash flow, solid revenue growth, and above-average operational metrics. Both companies demonstrate progress toward sustainable profitability while maintaining exposure to growing market segments.
Q3: Should I buy all these stocks or focus on specific opportunities?
Portfolio construction depends on your investment objectives, risk tolerance, and time horizon. Conservative investors might focus on established revenue-generating companies like Taboola, Dynavax, and TDS, which demonstrate positive cash flow and reasonable valuations. Growth-oriented investors might emphasize Owlet and Axsome, accepting higher volatility for exposure to rapid revenue growth. Development-stage biotech companies (Tyra, Omeros, CalciMedica) warrant smaller position sizes appropriate to their higher risk profiles. Diversification across multiple stocks reduces concentration risk while maintaining exposure to multiple growth drivers.
Q4: What are the biggest risks with these stock picks?
The primary risks vary by company type. For high-growth companies like Owlet and Axsome, significant cash burn and negative free cash flow indicate profitability challenges requiring continued revenue growth. For development-stage biotech companies, clinical trial failures and regulatory approval risks could eliminate shareholder value. For mature companies like TDS, secular headwinds in traditional telecommunications services create revenue pressure. Investors should carefully review each company's specific risk factors and establish appropriate position sizes reflecting these risks.
Q5: When is the best time to invest in these stocks?
Optimal entry timing depends on individual circumstances and market conditions. For established companies with positive cash flow, dollar-cost averaging over several months reduces timing risk. For high-growth companies, monitoring quarterly earnings and guidance updates provides signals for entry timing. For development-stage biotech, entry should follow careful analysis of clinical trial timelines and regulatory pathways. Current market conditions in early 2026 suggest reasonable valuations for growth stocks, but investors should avoid chasing momentum and instead focus on fundamental value relative to intrinsic value estimates.